Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Current Liabilities (2022 - 2025)

Taysha Gene Therapies' Total Current Liabilities history spans 4 years, with the latest figure at $28.6 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 2.4% year-over-year to $28.6 million; the TTM value through Sep 2025 reached $28.6 million, down 2.4%, while the annual FY2024 figure was $26.2 million, 28.65% down from the prior year.
  • Total Current Liabilities for Q3 2025 was $28.6 million at Taysha Gene Therapies, up from $25.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $180.5 million in Q3 2023 and bottomed at $22.6 million in Q1 2025.
  • The 4-year median for Total Current Liabilities is $36.8 million (2023), against an average of $47.6 million.
  • The largest annual shift saw Total Current Liabilities soared 444.53% in 2023 before it plummeted 83.74% in 2024.
  • A 4-year view of Total Current Liabilities shows it stood at $62.8 million in 2022, then plummeted by 41.46% to $36.8 million in 2023, then decreased by 28.65% to $26.2 million in 2024, then rose by 9.17% to $28.6 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Total Current Liabilities are $28.6 million (Q3 2025), $25.3 million (Q2 2025), and $22.6 million (Q1 2025).